The 340B discount program—which requires manufacturers to provide outpatient drugs to eligible health care entities at sharply reduced prices—continues to be both controversial and confusing.
In the post-Dobbs world, where a woman’s ability to get an abortion is left to individual states, dissemination of information about abortion-related services has become crucial to ensuring women can access abortion care.
In the aftermath of the Dobbs v. Jackson Supreme Court decision, there is ongoing discussion about the role that medication abortion—particularly tele-medication abortion (teleMAB)— will play in connecting women to abortion services.
Although increasing representation of underserved populations in clinical trials has been a long-standing goal for industry, providers and patients alike, progress to date has been slow.
To benefit fully from America’s health care system, people need both timely access to health care services and comprehensive health coverage to defray the cost of those services.
Americans are strongly focused on the upcoming midterm elections.
The Inflation Reduction Act of 2022 (IRA) includes the most dramatic change to U.S. drug price regulation in history.
In late June, California’s Governor Newsom signed the California Health Care Quality and Affordability Act, establishing a new Office of Health Care Affordability (OHCA) within the Department of Health Care Access and Information (HCAI).
The Inflation Reduction Act will make arguably the most significant changes to U.S. prescription drug pricing regulations ever, but certainly since the creation of the Medicaid Drug Rebate Program in 1990.
The United States continues to face a behavioral health crisis that has worsened due to the COVID-19 pandemic. In 2021, nearly 40% of adults reported symptoms of depression or anxiety, an increase from 10% in 2019.